EYEN FDA NEWS : Formosa And AimMax Therapeutics Secure FDA Approval For Clobetasol Propionate Ophthalmic Suspension 0.05%, For Treatment Of Post-Operative Inflammation And Pain Following Ocular Surgery
5:59 pm ET March 4, 2024 (Benzinga) Print
"With FDA approval now secured, we look forward to working with our U.S. commercialization partner, Eyenovia, Inc., to reach ophthalmologists and ocular surgery patients, while in parallel working to expand into additional territories and advance our earlier stage pipeline," sais aid Erick Co, President and CEO of Formosa Pharmaceuticals
All posts are my opinion and are not recommendations to buy or sell